PGG glucan(PGG glucan) - 药物靶点：CD11b x CD32A_在研适应症：乳腺癌_专利_临床

概要

基本信息

药物类型

聚合物

别名

Betafectin、Imprime、Imprime PGG

+ [4]

靶点

CD11b x CD32A

作用机制

CD11b激活剂(integrin subunit alpha M activators)、CD32A激活剂(低亲和力免疫球蛋白γFc区受体II-a激活剂)、免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

乳腺癌

非在研适应症

大肠腺癌晚期非小细胞肺癌复发性结直肠癌+ [6]

原研机构

Biothera Pharmaceuticals, Inc. (Delaware)

在研机构

Hibercell, Inc.初创企业

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

18

项与 PGG glucan 相关的临床试验

NCT05484011

/ Terminated临床1期

P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy.
Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

开始日期2022-12-15

申办/合作机构

Hibercell, Inc.初创企业

[+1]

NCT05159778

/ Completed临床2期

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled.
The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.

开始日期2021-11-09

申办/合作机构

Hibercell, Inc.初创企业

[+1]

CTRI/2021/10/037380

/ Not yet recruiting临床3期

An Open Label, Prospective, Randomized, Comparative, Multiple Arm Clinical Study to Evaluate the Immunomodulatory Efficacy of Nichi Glucan in Comparison with Conventional Therapeutic Regimen in Adult Subjects with Covid-19 caused by SARS-COV2 (B-COV)

开始日期2021-10-25

申办/合作机构-

100 项与 PGG glucan 相关的临床结果

登录后查看更多信息

100 项与 PGG glucan 相关的转化医学

登录后查看更多信息

100 项与 PGG glucan 相关的专利（医药）

登录后查看更多信息

268

项与 PGG glucan 相关的文献（医药）

2024-12-09·Journal of biomolecular structure & dynamics

Structural insights into modeling of hepatitis B virus reverse transcriptase and identification of its inhibitors from potential medicinal plants of Western Ghats: an in silic o and in vitro study

Article

作者: Roy, Subarna ; Deshpande, Sanjay H. ; Charla, Rajitha ; Harish, Darasaguppe R. ; Hegde, Harsha V. ; Patil, Vishal S. ; Jalalpure, Sunil S. ; Vetrivel, Umashankar ; Bhandare, Vishwambhar Vishnu

The present study was proposed to model full-length HBV-RT and investigate the intermolecular interactions of known inhibitor and libraries of phytocompounds to probe the potential natural leads by in silico and in vitro studies. Homology modeling of RT was performed by Phyre2 and Modeller and virtual screening of ligands implemented through POAP pipeline. Molecular dynamics (MD) simulation (100 ns) and MM-GBSA calculations were performed using Schrodinger Desmond and Prime, respectively. Phytocompounds probable host protein targets gene set pathway enrichment and network analysis were executed by KEGG database and Cytoscape software. Prioritized plant extracts/enriched fraction LC-MS analysis was performed and along with pure compound, RT inhibitory activity, time-dependent HBsAg and HBeAg secretion, and intracellular HBV DNA, and pgRNA by qRT-PCR was performed in HepG2.2.15 cell line. Among the screened chemical library of 268 phytocompounds from 18 medicinal plants, 15 molecules from Terminalia chebula (6), Bidens pilosa (5), and Centella asiatica (4)) were identified as potential inhibitors of YMDD and RT1 motif of HBV-RT. MD simulation demonstrated stable interactions of 15 phytocompounds with HBV-RT, of which 1,2,3,4,6-Pentagalloyl Glucose (PGG) was identified as lead molecule. Out of 15 compounds, 11 were predicted to modulate 39 proteins and 15 molecular pathways associated with HBV infection. TCN and TCW (500 µg/mL) showed potent RT inhibition, decreased intracellular HBV DNA, and pgRNA, and time-dependent inhibition of HBsAg and HBeAg levels compared to PGG and Tenofovir Disoproxil Fumarate. We propose that the identified lead molecules from T. chebula as promising and cost-effective moieties for the management of HBV infection.Communicated by Ramaswamy H. Sarma.

2024-11-01·Translational Lung Cancer Research

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017

Article

作者: Furqan, Muhammad ; Liu, Li ; Malhotra, Jyoti ; Feldman, Lawrence ; Hulbert, Alicia ; Shergill, Ardaman ; Mott, Sarah L ; Kennedy, Kathleen ; Pasquinelli, Mary M

Background:

Therapeutic strategies to engage anti-tumor innate immunity are still underdeveloped. Imprime PGG (imprime), a pathogen-associated molecular pattern (PAMP), through pattern recognition receptors, successfully illicit a broad-based innate immune response in preclinical models against various cancers. We aimed to study safety and efficacy of imprime in combination with pembrolizumab in advanced stage non-small cell lung cancer (NSCLC).

Methods:

We conducted an investigator-initiated, multi-institutional, single-arm, phase Ib/II trial in previously treated, advanced stage NSCLC patients. Primary endpoints were maximum-tolerated dose (MTD) of imprime for the phase Ib, and progression-free survival (PFS) for the phase II study (NCT03003468).

Results:

All 33 eligible patients were included in the safety analysis. No dose-limiting toxicity was observed and the imprime dose of 4 mg/kg was determined as the MTD. Thirty patients treated at the MTD (phase Ib, 6; phase II, 24) were included in the efficacy analysis. Median length of follow-up was 10.8 months. Confirmed objective response rate was 10% [95% confidence interval (CI): 2-27%], with one complete and two partial responses. Median PFS was 2.6 months (95% CI: 1.4-7.0), and 6- and 12-month PFS rates were 37% and 17%, respectively. Median overall survival (OS) was 11.1 months, and 6- and 12-month OS rates were 75% and 46%. Univariate analysis was performed to assess the impact of age, sex, race, disease-stage, programmed death-ligand 1 (PD-L1) expression levels, and prior immunotherapy on PFS and OS. Of these, prior immunotherapy negatively influenced OS [hazard ratio (HR): 2.95, 95% CI: 1.21-7.24]. Overall, the combination was safe and tolerable.

Conclusions:

The combination of imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage NSCLC patients who previously progressed on anti-programmed death 1 (PD-1)/PD-L1 immunotherapies. Further investigation is needed to understand the effects of therapeutic PAMPs to mount a strong innate immune response against cancer.

2024-10-01·Small

Dual‐Drug Nanomedicine Assembly with Synergistic Anti‐Aneurysmal Effects via Inflammation Suppression and Extracellular Matrix Stabilization

Article

作者: Peng, Cheng ; Wang, Hai Yang ; Zhu, Zi Jia ; Zu, Hong Lin ; Zhou, Wen Hu ; Wang, Qing Shan ; Yao, Ye ; Yue, Jie ; Zhuang, Pei Pei ; Peng, Chao ; Peng, Ying

Abstract:

Abdominal aortic aneurysm (AAA) represents a critical cardiovascular condition characterized by localized dilation of the abdominal aorta, carrying a significant risk of rupture and mortality. Current treatment options are limited, necessitating novel therapeutic approaches. This study investigates the potential of a pioneering nanodrug delivery system, RAP@PFB, in mitigating AAA progression. RAP@PFB integrates pentagalloyl glucose (PGG) and rapamycin (RAP) within a metal–organic‐framework (MOF) structure through a facile assembly process, ensuring remarkable drug loading capacity and colloidal stability. The synergistic effects of PGG, a polyphenolic antioxidant, and RAP, an mTOR inhibitor, collectively regulate key players in AAA pathogenesis, such as macrophages and smooth muscle cells (SMCs). In macrophages, RAP@PFB efficiently scavenges various free radicals, suppresses inflammation, and promotes M1‐to‐M2 phenotype repolarization. In SMCs, it inhibits apoptosis and calcification, thereby stabilizing the extracellular matrix and reducing the risk of AAA rupture. Administered intravenously, RAP@PFB exhibits effective accumulation at the AAA site, demonstrating robust efficacy in reducing AAA progression through multiple mechanisms. Moreover, RAP@PFB demonstrates favorable biosafety profiles, supporting its potential translation into clinical applications for AAA therapy.

9

项与 PGG glucan 相关的新闻（医药）

2024-10-23

·BioSpace

HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA’s Fast Track program aims to facilitate the development, and expedite the review, of novel potential therapies that are designed to treat serious conditions and have the potential to address significant unmet medical need. “We are proud to announce the grant of Fast Track designation by the FDA,” said Jonathan Lanfear, President & CEO of HiberCell. Receiving Fast Track designation highlights the FDA’s recognition of the robust preclinical data generated to date for HC-7366 and the potential for HC-7366 to address the significant unmet need that exists in R/R AML.” Mr. Lanfear continued, “HC-7366 was the first GCN2-activator to enter the clinic in AML and is the only GCN2-targeting agent to receive Fast Track designation for the treatment of AML, validating our preclinical and translational efforts. We plan to leverage the Fast-Track designation to work closely with the FDA to facilitate and, potentially accelerate the development of HC-7366 in AML.” HC-7366 is currently under clinical investigation in both solid and liquid tumor settings. The Phase 1b study in AML (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in relapsed/refractory (R/R) AML or MDS AML. This study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in a R/R AML population. Dependent on observations in the dose escalation portion, this study may include additional combination and monotherapy expansions. About HC-7366 HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with standard of care agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in R/R AML (NCT06285890). About HiberCell HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. For Media/Investor Inquiries: IR@hibercell.com

临床1期快速通道临床2期

2024-05-29

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

May 28, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML). "We are excited to announce the first patient dosed in this study," said Jonathan Lanfear, President & CEO of HiberCell. "This study builds on the preclinical data we have presented at recent conferences, including the 2023 ASH Annual Meeting and Exposition, which support evaluation of HC-7366 in combination with venetoclax and azacitidine in AML patients with significant unmet need." The study’s principal investigator is Dr. Abhishek Maiti, assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Mr. Lanfear continued, "The initiation of this study along with our recently announced study of HC-7366 in clear cell renal cell carcinoma marks the continued advancement of HC-7366 and HiberCell. These are seminal combinatorial studies of HC-7366 with the potential to address large, targeted, and underserved patient populations. We look forward to seeing data for these studies throughout 2024 and 2025." The newly announced Phase 1b study (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with standard dosing of venetoclax and azacitidine in patients with relapsed/refractory (R/R) AML or MDS AML. The study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in combination with venetoclax and azacitidine in a R/R AML population. The study will enroll up to 18 patients. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in AML in combination with azacitidine and venetoclax (NCT06285890). HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床研究临床2期

2024-05-02

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

May 01, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The Phase 1b study (NCT06234605) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with belzutifan in patients with advanced ccRCC. This trial will also determine a recommended Phase 2 dose (RP2D) of HC-7366 in combination with fixed-dose belzutifan, 120 mg po qd. Dose escalation of HC-7366 in the combination, followed by an expansion phase will optimize dose evaluation. An independent HC-7366 monotherapy cohort is being evaluated in parallel. The study will enroll up to 80 patients at clinical sites across the US. Robert J. Motzer, MD., Section Head, Kidney Cancer, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) will be the lead Principal Investigator (PI) for the clinical trial. "The first patient dosed in this trial marks the beginning of an exciting new chapter in the clinical development of HC-7366," stated Cherry Thomas, M.D., Chief Medical Officer. "The combination of HC-7366 with belzutifan, a key agent for the treatment of clear cell renal cell carcinoma, offers a potentially promising novel and differentiated treatment in a setting with major unmet need and limited treatment options for patients. We recently presented key aspects of the significant preclinical data in support of the combination at the 2024 American Association for Cancer Research Annual Conference." WELIREG® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in preclinical models of both solid and liquid tumors. HC-7366 is currently under clinical development in a Phase 1b study in clear cell renal cell carcinoma in combination with belzutifan. HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床2期AACR会议

100 项与 PGG glucan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
KRAS 野生型结直肠癌	临床3期	美国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	法国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	德国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	波多黎各	Hibercell, Inc.初创企业	2011-04-01
乳腺癌	临床2期	-	Hibercell, Inc.初创企业	2022-04-28
皮肤黑色素瘤	临床2期	美国	Hibercell, Inc.初创企业	2021-08-15
复发性惰性非霍奇金淋巴瘤	临床2期	美国	Hibercell, Inc.初创企业	2014-12-01
难治性惰性非霍奇金淋巴瘤	临床2期	美国	Hibercell, Inc.初创企业	2014-12-01
晚期非小细胞肺癌	临床2期	美国	Hibercell, Inc.初创企业	2009-08-01
晚期非小细胞肺癌	临床2期	德国	Hibercell, Inc.初创企业	2009-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03003468 (BTCRC LUN 15-017, Pubmed \| Transl Lung Cancer Res)	临床1/2期	非小细胞肺癌	33	Imprime PGG 4 mg/kg + Pembrolizumab	製製顧鹹鑰襯餘襯齋壓(選齋憲夢憲獵簾鏇鹽蓋) = 鑰餘糧蓋餘顧鹹獵憲衊襯膚鹹膚襯蓋壓範鹹壓 (齋壓網製鬱醖襯壓艱顧 ) 更多	不佳	2024-11-01
NCT05159778 (ASCO2022)	临床2期	转移性乳腺癌	47	Odetiglucan 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	鹹構觸餘蓋鑰積範壓顧(構壓簾網壓夢夢鹽鏇夢) = 廠選鏇鏇齋廠蓋簾齋繭鏇膚鹹選齋壓壓淵鏇構 (製鹹顧糧繭膚獵鹹淵繭 ) 更多	-	2022-06-02
Abstract OT1-18-05 (SABCS2022)	临床2期	PD-L1-positive	47	Imprime PGG 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	網鏇廠淵鹽築膚網齋鑰(繭顧選廠選鏇糧蓋廠窪) = 鬱憲醖糧築獵淵衊繭廠顧膚願膚繭願構鏇鑰選 (憲網壓築網糧積艱積餘 ) 更多	积极	2022-02-15
NCT03003468 (BTCRC-LUN15-017, WCLC2021 \| WCLC2021) 人工标引	临床1/2期	非小细胞肺癌	35	Pembro+Imprime PGG (phase Ib)	築膚積齋夢製選選鹹蓋(積醖製餘衊衊醖壓壓鹹) = 廠鹽襯觸製艱餘餘顧齋築廠艱餘壓鹹膚鑰範顧 (膚窪糧壓齋艱艱顧鹽憲, 1.28 ~ 27.8) 更多	不佳	2021-09-08
NCT03003468 (BTCRC-LUN15-017, WCLC2021 \| WCLC2021) 人工标引	临床1/2期	非小细胞肺癌	35	Pembro+Imprime PGG (phase II)	築膚積齋夢製選選鹹蓋(積醖製餘衊衊醖壓壓鹹) = 鏇鹽鏇壓壓壓鏇醖衊構築廠艱餘壓鹹膚鑰範顧 (膚窪糧壓齋艱艱顧鹽憲, 1.35 ~ 5.13) 更多	不佳	2021-09-08
NCT02086175 (CTgov)	临床2期	难治性惰性非霍奇金淋巴瘤 \| 复发性惰性非霍奇金淋巴瘤	25	Imprime PGG+Rituximab	蓋艱顧顧淵糧網壓遞壓(構襯膚醖餘積糧簾鹽網) = 製齋製選壓繭願艱願顧憲選廠鹹鑰築窪觸遞壓 (築積襯鬱遞鹽願憲膚鬱, 蓋齋膚顧構鏇構顧齋鏇 ~ 築鑰鑰網顧鹽構憲糧遞) 更多	-	2021-01-07
NCT02981303 (IMPRIME 1, AACR2020)	临床2期	转移性三阴性乳腺癌	44	Imprime PGG + Pembrolizumab	製鬱鹽襯願淵鏇鏇鑰壓(膚壓齋襯願鏇觸壓餘糧) = 範襯獵簾製遞窪憲鏇鹽簾夢築衊願齋淵鬱壓築 (壓鑰衊鹹構糧鏇壓構遞, 7.9 ~ 29.4) 更多	积极	2020-08-15
NCT02981303 (Phase 2, SITC2020)	临床2期	转移性黑色素瘤	20	Imprime PGG (Imprime)	蓋鬱遞糧繭襯衊構醖壓(鹽窪壓蓋構廠壓願範衊) = 夢觸顧顧憲襯鬱遞繭糧餘醖壓壓糧選獵餘遞鏇 (簾淵襯構鬱壓選淵願壓 ) 更多	积极	2020-04-15
NCT02981303 (SABCS2020)	临床2期	三阴性乳腺癌	44	Imprime PGG + Pembrolizumab	觸窪製糧鑰範顧壓遞鬱(選窪鏇衊糧製繭壓網廠) = 襯廠鏇鏇鏇淵構選蓋築鑰繭鹽鹽選壓築蓋鏇蓋 (淵鏇窪淵製齋範構願網 ) 更多	积极	2020-02-15
NCT00874107 (Pubmed \| J Immunother Cancer) 人工标引	临床2期	非小细胞肺癌一线	92	bevacizumab+carboplatin+paclitaxel+BTH1677	觸衊壓膚壓夢網壓鬱蓋(壓窪獵顧鑰餘糧鑰膚襯) = 廠築積構鹹範獵選襯願選鬱餘膚襯齋範網壓簾 (鏇遞窪獵齋蓋膚鹹顧齋 ) 更多	积极	2018-02-27
NCT00874107 (Pubmed \| J Immunother Cancer) 人工标引	临床2期	非小细胞肺癌一线	92	bevacizumab+carboplatin+paclitaxel	觸衊壓膚壓夢網壓鬱蓋(壓窪獵顧鑰餘糧鑰膚襯) = 鑰鬱窪襯簾襯糧鹹願鹹選鬱餘膚襯齋範網壓簾 (鏇遞窪獵齋蓋膚鹹顧齋 ) 更多	积极	2018-02-27
NCT00874848 (Pubmed \| Invest New Drugs) 人工标引	临床2期	非小细胞肺癌一线	90	cetuximab+carboplatin+paclitaxel+BTH1677	簾願鏇鏇網餘餘窪獵壓(觸範鬱構鏇鹽繭鹹網齋) = 製願願糧觸憲艱網遞觸築獵廠製獵顧遞鬱衊簾 (顧選鏇餘積廠憲範蓋鬱 ) 更多	积极	2017-06-01
NCT00874848 (Pubmed \| Invest New Drugs) 人工标引	临床2期	非小细胞肺癌一线	90	cetuximab+carboplatin+paclitaxel	簾願鏇鏇網餘餘窪獵壓(觸範鬱構鏇鹽繭鹹網齋) = 鏇積窪顧築獵膚壓膚襯築獵廠製獵顧遞鬱衊簾 (顧選鏇餘積廠憲範蓋鬱 ) 更多	积极	2017-06-01